Syndax Pharmaceuticals (NASDAQ:SNDX) disclosed that its Chief Financial Officer, Keith A. Goldan, completed a sale of 3,410 shares of common stock on February 9, 2026. The shares were sold at $21.028 apiece, bringing the gross proceeds of the transaction to about $71,705.
Following this disposition, Goldan's direct ownership in Syndax stands at 140,429 shares. Company filings indicate the sale was carried out to meet tax withholding obligations associated with the vesting of restricted stock units.
Separately, Syndax has been active on the scientific front. At the 67th American Society of Hematology Annual Meeting, the company presented data for its FDA-approved menin inhibitor, Revuforj. The results showed a 77% overall response rate among acute leukemia patients, and 75% of those patients achieved measurable residual disease negativity.
Across the ASH program, Syndax's portfolio - including Revuforj and Niktimvo - was referenced in 23 presentations and the company supported multiple educational events at the meeting.
Investor interest is reflected in recent analyst commentary. B.Riley reiterated a Buy rating on Syndax and kept a $33.00 price target, citing momentum in sales for Niktimvo. H.C. Wainwright also maintained a Buy recommendation and set a $40.00 target, noting that Revuforj has shown durable responses in real-world settings consistent with trial outcomes. TD Cowen likewise reaffirmed a Buy stance, pointing to Syndax's substantial presence at ASH.
The share sale by the CFO was disclosed as a tax-related liquidity event tied to vested restricted stock units and does not carry additional detail in filings about further changes to executive holdings or planned transactions.
Summary
Keith A. Goldan sold 3,410 Syndax shares on February 9, 2026 at $21.028 to cover tax withholding on vested RSUs, leaving him with 140,429 shares. Concurrently, Syndax reported positive ASH meeting activity, including Revuforj data showing a 77% overall response rate and 75% MRD negativity, and received reiterated Buy ratings from several analysts.
Key points
- Insider sale: 3,410 shares sold by CFO at $21.028 on February 9, 2026, totaling about $71,705.
- Clinical highlights: Revuforj data at ASH reported a 77% overall response rate and 75% MRD negativity in acute leukemia patients.
- Analyst support: B.Riley, H.C. Wainwright, and TD Cowen have each reaffirmed Buy ratings with price targets reflecting confidence in Syndax's recent performance.
Risks and uncertainties
- The CFO's sale was executed to satisfy tax withholding on vested restricted stock units; filings do not provide additional information on future insider transactions.
- While ASH presentations and analyst endorsements signal positive momentum, filings cited here do not include details on longer-term commercial performance beyond the points noted by analysts.